Commentary: Where and how could biomarkers be used in 2016
Journal Title: The AAPS Journal - Year 2006, Vol 8, Issue 1
Abstract
Since the beginning of the human genome project there has been considerable speculation about how this resource and the knowledge creation it enabled would change therapeutic discovery, development, and delivery. As the project neared completion, considerable claims and predictions were made about the changes that soon would be forthcoming. Many of these early predictions failed to materialize, however, leading to further speculation about the reasons, including the role of the pharmaceutical industry in realizing the promise of “genomic medicine”. During this same period, considerable strides were made in other areas of molecular biology and medicine, and in response scientific thinking naturally evolved. Researchers and regulators moved from a genotype-centric view to a view that all biomarkers are potential tools to improve drug development and therapeutic decision making. Molecular biology is now seen as encouraging more “personalized medicine”—the closer alignment of biological information (derived from molecular diagnostics) and therapy selection. Meanwhile, there are growing concerns that increasing expenditures in pharmaceutical research and development are not sustainable and not reaping sufficient gains for shareholders or society at large. Thus, there is new speculation about how biomarkers, personalized medicine, and the industry will interact and create value for patients. This overview seeks to explore the issues driving pharmaceutical productivity and the likely contribution of biomarkers in the future.
Authors and Affiliations
M. J. Finley Austin, Lee Babiss
Keywords
Related Articles
- EP ID EP681653
- DOI 10.1208/aapsj080122
- Views 77
- Downloads 0
Performance of Nonlinear Mixed Effects Models in the Presence of Informative Dropout
Informative dropout can lead to bias in statistical analyses if not handled appropriately. The objective of this simulation study was to investigate the performance of nonlinear mixed effects models with regard to bias a...
Solid Lipid Budesonide Microparticles for Controlled Release Inhalation Therapy
A solid lipid microparticle system containing budesonide was prepared by oil in water emulsification followed by spray drying. The solid lipid system was studied in terms of morphology, particle size distribution, crysta...
Editorial: Theme issue “Drug addiction—From basic research to therapies”
Comparison of the gravimetric, phenol red, and 14C-PEG-3350 methods to determine water absorption in the rat single-pass intestinal perfusion model
This study was undertaken to determine whether the gravimetric method provided an accurate measure of water flux correction and to compare the gravimetric method with methods that employ nonabsorbed markers (eg, phenol r...
Nonaqueous Gel for the Transdermal Delivery of a DTPA Penta-ethyl Ester Prodrug
Diethylenetriamine pentaacetic acid penta-ethyl ester, designated as C2E5, was successfully incorporated into a nonaqueous gel for transdermal delivery. The thermal and rheological properties of a formulation containing...